Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 2.0 | 5.0 |
Min SIP Amount | ₹100 | ₹500 |
Expense Ratio | 1.05 | 1.93 |
NAV | ₹19.56 | ₹431.69 |
Fund Started | 06 Oct 2020 | 04 Jun 1999 |
Fund Size | ₹156.35 Cr | ₹3689.28 Cr |
Exit Load | - | Exit load of 0.50% if redeemed within 15 days |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 9.38% | 20.38% |
3 Year | 19.34% | 29.14% |
5 Year | - | 24.49% |
1 Year
3 Year
5 Year
Equity | 99.95% | 96.09% |
Cash | -0.07% | 3.83% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.29% |
Max Healthcare Institute Ltd. | 6.68% |
Divi's Laboratories Ltd. | 6.03% |
Cipla Ltd. | 5.87% |
Dr. Reddy's Laboratories Ltd. | 5.58% |
Apollo Hospitals Enterprise Ltd. | 5.29% |
Eli Lilly And Co | 4.86% |
Lupin Ltd. | 3.41% |
Johnson & Johnson Ltd. | 3.05% |
Torrent Pharmaceuticals Ltd. | 2.87% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.73% |
Divi's Laboratories Ltd. | 7.39% |
Max Healthcare Institute Ltd. | 6.40% |
Lonza Group Ag | 4.81% |
Cipla Ltd. | 4.77% |
Lupin Ltd. | 4.46% |
Mankind Pharma Ltd. | 3.75% |
Krishna Institute of Medical Sciences Ltd | 3.34% |
Fortis Healthcare Ltd. | 3.22% |
Acutaas Chemicals Ltd. | 3.19% |
Name | Bhavesh Jain | Tanmaya Desai |
Start Date | 01 Oct 2021 | 27 Jun 2011 |
Name
Start Date
Description | The scheme seeks to invest in stocks comprising of the MSCI India Domestic & World Healthcare 45 Index with the objective to provide investment returns that, before expenses, closely corresponds to the returns equivalent to the index, subject to tracking errors. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 06 Oct 2020 | 04 Jun 1999 |
Description
Launch Date